
    
      A total of 64 participants will be enrolled for challenge and divided into four groups as
      follows:

        -  20 participants to receive R21/Matrix M (R21/MM) with intradermal PfSPZ Challenge;

        -  20 participants to receive viral-vectored ME-TRAP with intradermal PfSPZ Challenge;

        -  10 participants to receive R21/MM with direct venous inoculation PfSPZ Challenge; and

        -  14 participants comprising of the control group with intradermal PfSPZ Challenge.

      Blood tests and clinical assessments will be conducted to screen out participants with health
      conditions that may impact participation in the study.
    
  